Efficacy and safety of aerosolized tobramycin in cystic fibrosis

Pediatric Pulmonology

Volumn 32, Issue 4, 2001, Pages 314-327

  Pai, Vinita B ^a   Nahata, Milap C ^b  

^a St Luke's Boise Regional Medical Center   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

Aerosols; Cystic fibrosis; Tobramycin

Indexed keywords

CREATININE; PLACEBO; TOBRAMYCIN;

AEROSOL; ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SPUTUM LEVEL; HUMAN; LUNG FUNCTION; LUNG INFECTION; NEPHROTOXICITY; OSMOLALITY; OTOTOXICITY; PATIENT MONITORING; PH; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SPUTUM;

ADMINISTRATION, INHALATION; ADOLESCENT; AEROSOLS; BIOLOGICAL AVAILABILITY; CHILD; CHILD, PRESCHOOL; CONSUMER PRODUCT SAFETY; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; NEBULIZERS AND VAPORIZERS; SENSITIVITY AND SPECIFICITY; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 0034790975     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.1125     Document Type: Article

References (64)

1. Cystic fibrosis: Molecular biology and therapeutic implications
2. Cystic fibrosis: A disease of electrolyte transport
3. Cystic fibrosis
4. In vitro activity of piperacillin, ticarcillin, and mezlocillin alone and in combination with aminoglycosides against Pseudomonas aeruginosa
5. Controlled trial of ceftazidime vs. ticarcillin and tobramycin in treatment of acute respiratory exacerbations in patients with cystic fibrosis
6. Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary Pseudomonas infection, and an exacerbation of respiratory symptoms
7. Anti-pseudomonal therapy in cystic fibrosis: Aztreonam and amikacin versus ceftazidime and amikacin administered intravenously followed by oral ciprofloxacin
8. Clinical evaluation of meropenem versus ceftazidime for the treatment of Pseudomonas spp. Infections in cystic fibrosis patients
9. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis
10. Changing epidemiology of Pseudomonas aeruginosa infection in Danish cystic fibrosis patients (1974-1995)
11. Effect of dihydrostreptomycin on ribosome function in vivo
12. Deposition of aerosol in the respiratory tract
13. Quantitative deposition of aerosolized gentamicin in cystic fibrosis
14. The quantitative distribution of nebulised antibiotic in the lung in cystic fibrosis
15. Bioactivity of gentamicin in purulent sputum from patients with cystic fibrosis or bronchiectasis: Comparison with activity in serum
16. Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum
17. Biological variability of regional deposition of aerosol particles in the human respiratory tract
18. Absolute bioavailability and absorption characteristics of aerosolized tobramycin in adults with cystic fibrosis
19. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis
20. The quantitative distribution of nebulized antibiotic in the lung in cystic fibrosis
21. The relationship of age, gender and baseline lung function to serum and sputum concentrations [T] after administration of tobramycin solution for inhalation (TOBI™)
22. Efficacy of inhaled tobramycin in the treatment of pulmonary exacerbations in children with cystic fibrosis
23. Long-term tobramycin aerosol therapy in cystic fibrosis
24. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa
25. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
26. Serial changes in pulmonary function in children hospitalized with cystic fibrosis
27. Long term study of 105 patients with cystic fibrosis
28. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin and azlocillin-placebo
29. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
30. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
31. Alterations in osmolality of inhaled aerosols causing bronchoconstriction and cough, but absence of a permanent anion causes cough alone
32. Hyperosmolarity as the stimulus to asthma induced by hyperventilation
33. Mechanisms of cough and bronchoconstriction induced by distilled water aerosol
34. The role of titrable acidity in acid aerosol-induced bronchoconstriction
35. Airway responses to sulfate and sulfuric acid aerosols in asthmatics. An exposure-response relationship
36. Asthma induced by adrenergic aerosols
37. Paradoxical bronchospasm after inhalation of isoproterenol
38. Bronchospastic responses to aerosolized metabisulfite in asthmatic subjects: Potential mechanisms and clinical implications
39. Bronchoconstrictor properties of preservatives in ipratropium bromide (Atrovent) nebuliser solution
40. The contribution of histamine release to bronchoconstriction provoked by inhaled benzalkonium chloride in asthma
41. Nebulisation equipment a potential source of infection in gram negative pneumonias
42. Adverse reactions to the nondrug constituents of nebuliser solutions
43. Bronchial constriction after nebulized tobramycin preparations and saline in patients with cystic fibrosis
44. Effects of pH and osmolarity on aerosol-induced cough in normal volunteers
45. Osmolality and pH of anti-asthmatic drug solutions
46. Osmolality of substances used in the intensive care nursery
47. Osmolality of small volume IV
48. ASHP technical assistance bulletin on quality assurance for pharmacy-prepared sterile products
49. Comparative antimicrobial activity of FK037, cefpirome, ceftazidime and cefepime against aminoglycoside-sensitive and aminoglycoside-resistant Pseudomonas aeruginosa and Pseudomonas spp.
50. Concentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage
51. Development of resistance and cross resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations
52. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection
53. Histologic changes in the respiratory tract-induced by inhalation of xenobiotics: Physiologic adaptation or toxicity?
54. Interim analysis of data from an openlabel follow-on trial of inhaled tobramycin (PC-TNDS-004) in patients with cystic fibrosis
55. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
56. Long-term fungal cultures from sputum of patients with cystic fibrosis